-
1
-
-
84903720695
-
-
(eds) GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase no. 10 (Updated December 2010). Lyon, France: International Agency for Research on Cancer
-
Ferlay J, Shin HR, Bray F et al. (eds) GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase no. 10 (Updated December 2010). Lyon, France: International Agency for Research on Cancer 2010.
-
(2010)
-
-
Ferlay, J.1
Shin, H.R.2
Bray, F.3
-
2
-
-
84859753179
-
Malignant melanoma: the implications of cost for stakeholder innovation
-
Styperek A, Kimball AB. Malignant melanoma: the implications of cost for stakeholder innovation. Am J Pharm Benefits 2012; 4: 66-76.
-
(2012)
Am J Pharm Benefits
, vol.4
, pp. 66-76
-
-
Styperek, A.1
Kimball, A.B.2
-
3
-
-
18444374405
-
Mutations of the BRAF gene in human cancer
-
Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
-
(2002)
Nature
, vol.417
, pp. 949-954
-
-
Davies, H.1
Bignell, G.R.2
Cox, C.3
-
4
-
-
27844567142
-
Distinct sets of genetic alterations in melanoma
-
Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-2147.
-
(2005)
N Engl J Med
, vol.353
, pp. 2135-2147
-
-
Curtin, J.A.1
Fridlyand, J.2
Kageshita, T.3
-
5
-
-
84864285704
-
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
-
Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.
-
(2012)
Lancet
, vol.380
, pp. 358-365
-
-
Hauschild, A.1
Grob, J.J.2
Demidov, L.V.3
-
6
-
-
84882873880
-
An update on BREAK-3, a phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM)
-
abstr 9013
-
Hauschild A, Grob JJ, Demidov LV et al. An update on BREAK-3, a phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). J Clin Oncol 2013; 31 (suppl); abstr 9013.
-
(2013)
J Clin Oncol
, vol.31
, Issue.SUPPL.
-
-
Hauschild, A.1
Grob, J.J.2
Demidov, L.V.3
-
7
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
-
(2011)
N Engl J Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
-
8
-
-
70349570445
-
A systematic review of health-related quality of life in cutaneous melanoma
-
Cornish D, Holterhues C, van de Poll-Franse LV et al. A systematic review of health-related quality of life in cutaneous melanoma. Ann Oncol 2009; 20(suppl 6):vi51-vi58.
-
(2009)
Ann Oncol
, vol.20
, Issue.SUPPL. 6
-
-
Cornish, D.1
Holterhues, C.2
van de Poll-Franse, L.V.3
-
9
-
-
84903745610
-
-
European organisation for research and treatment of cancer: EORTC quality of life questionnaire (EORTC QLQ-C30), 24 April , date last accessed
-
European organisation for research and treatment of cancer: EORTC quality of life questionnaire (EORTC QLQ-C30); http://groups.eortc.be/qol/eortc-qlq-c30 (24 April 2014, date last accessed).
-
(2014)
-
-
-
10
-
-
0027417437
-
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology
-
Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
-
(1993)
J Natl Cancer Inst
, vol.85
, pp. 365-376
-
-
Aaronson, N.K.1
Ahmedzai, S.2
Bergman, B.3
-
11
-
-
8244243951
-
Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group
-
Osoba D, Aaronson N, Zee B et al. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group. Qual Life Res 1997; 6: 103-108.
-
(1997)
Qual Life Res
, vol.6
, pp. 103-108
-
-
Osoba, D.1
Aaronson, N.2
Zee, B.3
-
12
-
-
0028063346
-
Psychometric properties and responsiveness of the EORTC quality of life questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer
-
Osoba D, Zee B, Pater J et al. Psychometric properties and responsiveness of the EORTC quality of life questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994; 3: 353-364.
-
(1994)
Qual Life Res
, vol.3
, pp. 353-364
-
-
Osoba, D.1
Zee, B.2
Pater, J.3
-
13
-
-
0029033528
-
Test/retest study of the European Organization for Research and Treatment of Cancer core quality-of-life questionnaire
-
Hjermstad MJ, Fossa SD, Bjordal K et al. Test/retest study of the European Organization for Research and Treatment of Cancer core quality-of-life questionnaire. J Clin Oncol 1995; 13: 1249-1254.
-
(1995)
J Clin Oncol
, vol.13
, pp. 1249-1254
-
-
Hjermstad, M.J.1
Fossa, S.D.2
Bjordal, K.3
-
14
-
-
0029185935
-
The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy
-
Kaasa S, Bjordal K, Aaronson N et al. The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer 1995; 31A: 2260-2263.
-
(1995)
Eur J Cancer
, vol.31 A
, pp. 2260-2263
-
-
Kaasa, S.1
Bjordal, K.2
Aaronson, N.3
-
15
-
-
0031972496
-
Interpreting the significance of changes in health-related quality-of-life scores
-
Osoba D, Rodrigues G, Myles J et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139-144.
-
(1998)
J Clin Oncol
, vol.16
, pp. 139-144
-
-
Osoba, D.1
Rodrigues, G.2
Myles, J.3
-
16
-
-
53249086693
-
EORTC QLQ-C30 Reference Values
-
Brussels, Belgium: EORTC Publications
-
Scott NW, Fayers PM, Aaronson NK et al. EORTC QLQ-C30 Reference Values. Brussels, Belgium: EORTC Publications 2008.
-
(2008)
-
-
Scott, N.W.1
Fayers, P.M.2
Aaronson, N.K.3
-
17
-
-
33745296370
-
Psychological distress surrounding diagnosis of malignant and nonmalignant skin lesions at a pigmented lesion clinic
-
Al-Shakhli H, Harcourt D, Kenealy J. Psychological distress surrounding diagnosis of malignant and nonmalignant skin lesions at a pigmented lesion clinic. J Plast Reconstr Aesthet Surg 2006; 59: 479-486.
-
(2006)
J Plast Reconstr Aesthet Surg
, vol.59
, pp. 479-486
-
-
Al-Shakhli, H.1
Harcourt, D.2
Kenealy, J.3
-
18
-
-
1842503110
-
A quality-of-life study in high-risk (thickness >= or 2 mm) cutaneous melanoma patients in a randomized trial of 1-cm versus 3-cm surgical excision margins
-
Newton-Bishop JA, Nolan C, Turner F et al. A quality-of-life study in high-risk (thickness >= or 2 mm) cutaneous melanoma patients in a randomized trial of 1-cm versus 3-cm surgical excision margins. J Investig Dermatol Symp Proc 2004; 9: 152-159.
-
(2004)
J Investig Dermatol Symp Proc
, vol.9
, pp. 152-159
-
-
Newton-Bishop, J.A.1
Nolan, C.2
Turner, F.3
-
19
-
-
79952139727
-
American Society of Clinical Oncology statement: toward individualized care for patients with advanced cancer
-
Peppercorn JM, Smith TJ, Helft PR et al. American Society of Clinical Oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol 2011; 29: 755-760.
-
(2011)
J Clin Oncol
, vol.29
, pp. 755-760
-
-
Peppercorn, J.M.1
Smith, T.J.2
Helft, P.R.3
-
20
-
-
84860496547
-
Progression-free survival: meaningful or simply measurable?
-
Booth CM, Eisenhauer EA. Progression-free survival: meaningful or simply measurable? J Clin Oncol 2012; 30: 1030-1033.
-
(2012)
J Clin Oncol
, vol.30
, pp. 1030-1033
-
-
Booth, C.M.1
Eisenhauer, E.A.2
-
21
-
-
84880845767
-
Trametinib (T) vs chemotherapy (C) in patients with BRAF V600E+ metastatic melanoma (MM): quality of life (QOL) analysis
-
Schadendorf D, Milhem M, Demidov LV et al. Trametinib (T) vs chemotherapy (C) in patients with BRAF V600E+ metastatic melanoma (MM): quality of life (QOL) analysis. Pigment Cell Melanoma Res 2013; 26:154.
-
(2013)
Pigment Cell Melanoma Res
, vol.26
, pp. 154
-
-
Schadendorf, D.1
Milhem, M.2
Demidov, L.V.3
-
22
-
-
0346096833
-
Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine
-
Kiebert GM, Jonas DL, Middleton MR. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest 2003; 21: 821-829.
-
(2003)
Cancer Invest
, vol.21
, pp. 821-829
-
-
Kiebert, G.M.1
Jonas, D.L.2
Middleton, M.R.3
-
23
-
-
1842562211
-
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study
-
Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22: 1118-1125.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1118-1125
-
-
Avril, M.F.1
Aamdal, S.2
Grob, J.J.3
-
24
-
-
84896817855
-
Health related quality of life (HRQL) of patients receiving ipilimumab with dacarbazine as first-line treatment for unresectable stage III/IV melanoma
-
Kotapati S, Francis S, Sherrill B. Health related quality of life (HRQL) of patients receiving ipilimumab with dacarbazine as first-line treatment for unresectable stage III/IV melanoma. Pigment Cell Melanoma Res 2011; 24(5): 1037.
-
(2011)
Pigment Cell Melanoma Res
, vol.24
, Issue.5
, pp. 1037
-
-
Kotapati, S.1
Francis, S.2
Sherrill, B.3
-
25
-
-
84862172613
-
Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
-
Revicki DA, van den Eertwegh AJ, Lorigan P et al. Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health Qual Life Outcomes 2012; 10: 66.
-
(2012)
Health Qual Life Outcomes
, vol.10
, pp. 66
-
-
Revicki, D.A.1
Van den Eertwegh, A.J.2
Lorigan, P.3
-
26
-
-
0030967034
-
Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy
-
Fairclough DL. Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Stat Med 1997; 16: 1197-1209.
-
(1997)
Stat Med
, vol.16
, pp. 1197-1209
-
-
Fairclough, D.L.1
|